Effectiveness and Tolerability of LabiaStick#01 in Subjects With Symptomatic Non-hypertrophic Chronic Vulvar Dermatoses

Inclusion Criteria: * Able and willing to give written informed consent. * Woman, with 18 or more years. * Diagnosed with symptomatic non-hypertrophic chronic vulvar dermatoses. * A pruritus score of at least 20 on a 100-mm VAS-PR. * Willing and able to comply with the study requirements. * Participant of childbearing potential agrees to remain abstinent or to use an acceptable contraceptive measure for the entire duration of the study. * Participant not of childbearing potential (e.g., is not sexually active, whose current partner is not of reproductive potential). Exclusion Criteria: * Received systemic immunosuppressant therapy (e.g. systemic corticosteroids) within 4 weeks prior to admission. * Treated with daily topical therapy (e.g. topical corticosteroids, pimecrolimus, and tacrolimus) at the target vulvar area within 2 weeks prior to admission, which in the opinion of the investigator might compromise study results. * Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have an uncontrolled malignant disease. * Suffers from systemic or generalized infections (bacterial, viral or fungal). * Diagnosis of psoriasis, candidiasis, vulvar intraepithelial neoplasia or carcinoma of the vulva. * Pregnancy or breastfeeding. * Documented and consistent history of hypersensitivity reactions to similar topical products. * Any condition that in the opinion of the investigator might prevent the subject from completing the study or interfere with the interpretation of the study results.